دورية أكاديمية
أعرض في EDS

The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma.

التفاصيل البيبلوغرافية
العنوان: The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma.
المؤلفون: Fruytier AC; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium., Le Duff CS; Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain Louvain-la-Neuve, Belgium., Po C; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium., Magat J; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium., Bouzin C; Institut de Recherche Expérimentale et Clinique, Pole of Pharmacology, Angiogenesis and Cancer Research Laboratory, Université Catholique de Louvain Brussels, Belgium., Neveu MA; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium., Feron O; Institut de Recherche Expérimentale et Clinique, Pole of Pharmacology, Angiogenesis and Cancer Research Laboratory, Université Catholique de Louvain Brussels, Belgium., Jordan BF; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium., Gallez B; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain Brussels, Belgium.
المصدر: Frontiers in pharmacology [Front Pharmacol] 2016 Dec 23; Vol. 7, pp. 506. Date of Electronic Publication: 2016 Dec 23 (Print Publication: 2016).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Media]
مستخلص: In recent clinical studies, vascular disrupting agents (VDAs) are mainly used in combination with chemotherapy. However, an often overlooked concern in treatment combination is the VDA-induced impairment of chemotherapy distribution in the tumor. The work presented here investigated the impact of blood flow shutdown induced by Combretastatin A4 (CA4) on gemcitabine uptake into mouse hepatocarcinoma. At 2 h after CA4 treatment, using DCE-MRI, a significant decrease in the perfusion-relevant parameters K trans and Vp were observed in treated group compared with the control group. The blood flow shutdown was indeed confirmed by a histology study. In a third experiment, the total gemcitabine uptake was found to be significantly lower in treated tumors, as assessed in a separate experiment using ex vivo fluorine nuclear magnetic resonance spectroscopy. The amount of active metabolite gemcitabine triphosphate was also lower in treated tumors. In conclusion, the blood flow shutdown induced by VDAs can impact negatively on the delivery of small cytotoxic agents in tumors. The present study outlines the importance of monitoring the tumor vascular function when designing drug combinations.
References: Cancer Res. 1992 Feb 1;52(3):533-9. (PMID: 1732039)
Front Oncol. 2013 Oct 01;3:259. (PMID: 24102047)
Clin Cancer Res. 2001 Oct;7(10):3263-8. (PMID: 11595723)
Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77. (PMID: 22330689)
Invest Radiol. 1989 Mar;24(3):224-7. (PMID: 2753638)
Br J Cancer. 2007 Jan 29;96(2):189-95. (PMID: 17211479)
Cancer Res. 1966 Jan;26(1):143-8. (PMID: 5901739)
Nat Med. 1995 Jan;1(1):27-31. (PMID: 7584949)
J Magn Reson Imaging. 1999 Sep;10(3):223-32. (PMID: 10508281)
Acta Oncol. 2010 Oct;49(7):906-13. (PMID: 20831477)
Clin Cancer Res. 2002 Jun;8(6):1974-83. (PMID: 12060643)
Adv Drug Deliv Rev. 2012 Dec 1;64(Suppl):353-365. (PMID: 24511174)
Br J Cancer. 1999 Dec;81(8):1318-27. (PMID: 10604728)
Neoplasia. 2005 Oct;7(10 ):957-66. (PMID: 16242078)
Cancer Res. 2005 Jul 1;65(13):5785-91. (PMID: 15994954)
Solid State Nucl Magn Reson. 2002 Dec;22(4):458-483. (PMID: 12637147)
Cancer Treat Rev. 2011 Feb;37(1):63-74. (PMID: 20570444)
NMR Biomed. 2007 Apr;20(2):128-40. (PMID: 17006886)
NMR Biomed. 2014 Nov;27(11):1403-12. (PMID: 25323069)
Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. (PMID: 21431415)
Nat Rev Cancer. 2005 Jun;5(6):423-35. (PMID: 15928673)
Ann Oncol. 2006 May;17 Suppl 5:v7-12. (PMID: 16807468)
Clin Cancer Res. 1996 Feb;2(2):359-67. (PMID: 9816179)
Cancer Chemother Pharmacol. 1997;39(6):541-6. (PMID: 9118467)
Magn Reson Med. 2014 Feb;71(2):544-50. (PMID: 23440927)
Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S164-82. (PMID: 20461374)
Clin Cancer Res. 2004 Jan 15;10 (2):415-27. (PMID: 14760060)
Science. 2009 Jun 12;324(5933):1457-61. (PMID: 19460966)
NMR Biomed. 2002 Apr;15(2):89-98. (PMID: 11870904)
Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52. (PMID: 12497205)
J Clin Oncol. 2012 Mar 1;30(7):760-1; author reply 761-3. (PMID: 22291088)
Cancer Sci. 2003 Feb;94(2):200-4. (PMID: 12708497)
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6. (PMID: 12459376)
Cancer Res. 2001 Apr 1;61(7):3039-44. (PMID: 11306485)
فهرسة مساهمة: Keywords: 19F NMR; DCE-MRI; drug delivery; tumor perfusion; vascular disrupting agent
تواريخ الأحداث: Date Created: 20170110 Latest Revision: 20201001
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5179558
DOI: 10.3389/fphar.2016.00506
PMID: 28066252
قاعدة البيانات: MEDLINE
الوصف
تدمد:1663-9812
DOI:10.3389/fphar.2016.00506